Nohla Therapeutics announces Lawrence Gozlan to its Board after closing a $21m private Financing Round

– USA, WA – Nohla Therapeutics Inc. (Nohla), a leading developer of cellular therapies for haematological disorders and immunological diseases, announced today that it has closed an oversubscribed first capital raising round. Nohla closed the round with US $21M raised from several institutional investors.

In conjunction with this capital raising, Nohla announced a new leadership appointment today. Mr. Lawrence Gozlan will join the company’s Board of Directors. Mr. Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. With 15 years of experience in investing and banking, Mr. Gozlan has expertise in all areas of investment management and deep roots in the scientific and biotech communities.

Prior to Scientia Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte.

Mr. Gozlan currently serves as a Director on the Board of Prana Biotechnology (NASDAQ:PRAN). He holds a Bachelor of Science with Honours in immunology from the University of Melbourne.

“I am delighted to join the Board of Nohla Therapeutics,” said Mr. Gozlan. “The cellular therapy platform developed by Dr. Colleen Delaney and Dr. Irwin Bernstein at the Fred Hutch provides an unmatched clinical and commercial advantage over all other approaches currently being developed in the fields of stem cell transplant and immuno-oncology. The clinical data generated thus far is exceptional and the technology platform has the potential to be the cornerstone of next generation cellular therapies.”

Mr. Michael Sistenich, Chief Business Officer for Nohla stated, “We are delighted that Lawrence has agreed to lend his experience and expertise to Nohla. His leadership in the biotech sector will be invaluable to Nohla in the years ahead as we aim to transform the treatment paradigm of stem cell transplants and build a broad pipeline of innovative allogeneic immunotherapies.”

About Nohla Therapeutics

Nohla Therapeutics Inc. (Nohla) is a clinical stage company developing world leading cellular therapies. Leveraging technology developed over the past two decades at the Fred Hutchinson Cancer Research Center, Nohla’s lead product is an ex vivo expanded hematopoietic stem and progenitor cell therapy derived from umbilical cord blood that is used clinically without any requirement for HLA matching. The product is truly ‘off-the-shelf’ and is available to all potential patients on demand at the time of treatment. Hematopoietic stem cell transplant remains the only proven cure for many hematologic malignancies, and multiple clinical trials infusing Nohla’s lead product have demonstrated reduced time to neutrophil and platelet engraftment, decreased rates of severe acute graft versus host disease and decreased transplant related mortality, and best-in-class improvements in overall survival. This expanded hematopoietic cell therapy has also been safely used in patients following high dose chemotherapy to prevent life threatening complications that result from prolonged neutropenia. Thus, in addition to treating many thousands of cancer patients each year who undergo high dose chemotherapy regimens, this product could be used to prevent and treat infectious complications in patients with neutropenia, regardless of cause.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.